Also trades as: 0J9P.L (LSE) · $vol 0M
INCY NASDAQ
Incyte Corporation
1W: -0.0%
1M: -6.6%
3M: -8.3%
YTD: +15.0%
1Y: +27.7%
3Y: +111.5%
5Y: +78.1%
$116.60
+3.29 (+2.90%)
Weekly Expected Move ±4.1%
$106
$111
$116
$120
$125
Credit Risk of going bust: lower than 96% of companies Debt: 0.2% of company value Bonds: none of note held by US funds details ▾
Of US companies ranked in the safest four tenths, about 1 in 3,500 filed for bankruptcy within a year (2020-2025).
If the stock fell to about $0.01 (down more than 99.9%), Incyte Corporation would be worth roughly what it owes.
Total debt $38.3M against a stock market value of $23.63B.
Distance to default 21.19 (Merton model): prices to 2026-10-27, balance sheet 2026-06-30, debt counted $19.1M (short-term plus half of long-term), stock volatility 33.6%; Altman Z'' 10.50. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
If the stock fell to about $0.01 (down more than 99.9%), Incyte Corporation would be worth roughly what it owes.
Total debt $38.3M against a stock market value of $23.63B.
Distance to default 21.19 (Merton model): prices to 2026-10-27, balance sheet 2026-06-30, debt counted $19.1M (short-term plus half of long-term), stock volatility 33.6%; Altman Z'' 10.50. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Supply Chain Overview
6 relationships1
As Filer
counterparties named
5
As Counterparty
mentioned by others
1
Rel. Types
2021-09-27
Earliest Filing
2025-11-04
Latest Filing
partner: 1
Counterparties (Filed by INCY)
1 relationshipsCompanies named in INCY's SEC 8-K filings as business counterparties.
Mentioned As Counterparty
5 mentionsOther companies that named INCY in their SEC 8-K filings.
| Filed By | Relationship | Summary | Filing Date | SEC |
|---|---|---|---|---|
| PRLD Prelude Therapeutics Inc | target | Incyte acquired Prelude's JAK2V617F inhibitor program via an exclusive option agreement and purchased $25M in non-voting | 2025-11-04 | View |
| MGNX MACROGENICS INC | partner | Original licensor of ZYNYZ under the Global Collaboration and License Agreement. | 2025-06-10 | View |
| AGEN AGENUS INC | partner | Counterparty to a License, Development and Commercialization Agreement covering assets sold to Ligand. | 2024-05-30 | View |
| AGEN AGENUS INC | partner | Original licensor under a License, Development and Commercialization Agreement with Agenus Inc., whose milestone payment | 2024-05-07 | View |
| SNDX Syndax Pharmaceuticals Inc | partner | Entered into a collaboration and license agreement for worldwide development and commercialization of axatilimab, includ | 2021-09-27 | View |
Recent 8-K Filings (20)
| Filing Date | Description | Type | SEC |
|---|---|---|---|
| 2026-08-31 | Other Events | View | |
| 2026-07-28 | Earnings Release; Exhibits | View | |
| 2026-07-06 | Other Events; Exhibits | View | |
| 2026-06-22 | Other Events | View | |
| 2026-06-09 | Shareholder Vote | View | |
| 2026-06-08 | Other Events | View | |
| 2026-04-28 | Earnings Release | View | |
| 2026-03-30 | Officer/Director Change | View | |
| 2026-03-26 | Officer/Director Change; Exhibits | View | |
| 2026-03-06 | Other Events | View | |
| 2026-02-10 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2025-12-12 | Departure/Election of Directors; Appointment of Officers | View | |
| 2025-10-28 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2025-10-03 | Departure/Election of Directors; Appointment of Officers | View | |
| 2025-08-07 | Departure/Election of Directors; Appointment of Officers | View | |
| 2025-07-29 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2025-06-27 | Departure/Election of Directors; Appointment of Officers; Financial Statements and Exhibits | View | |
| 2025-06-11 | Departure/Election of Directors; Appointment of Officers; Submission of Matters to a Vote of Securit | View | |
| 2025-05-14 | Other Events | View | |
| 2025-04-29 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View |
Data extracted from SEC EDGAR 8-K filings using NLP. Relationships are as disclosed in filing text.
Covers 2021–2026. View on SEC EDGAR